Bhavani Perumal Kannabiran, Natarajan Alangudi Palaniappan, Tamizhselvan Manoharan, Paul Kumaran Paramasivam, Jitendra Kumar Saini, Mohammed Soheb Ansari, Lavanya Jayabal, Ashutosh N Aggarwal, Rajiv Garg, Balaji Subramanyam, Deepika Thakur, Shilpa Pantula, Ramesh P M, Vijayachandar Gs, Saravanan Natarajan, Radha Krishnan Ammayappan, Bhalla Manpreet, Mangalambal Ganesan, Dhanalakshmi Angamuthu, Ponnuraja Chinnaiyan, Manjula Singh, Padmapriyadarsini Chandrasekaran, Soumya Swaminathan
BACKGROUND: Globally, no trial data are available on head-to-head comparison between 10 mg/kg and 25/35 mg/kg rifampicin in treating pulmonary tuberculosis during study initiation. METHODS: A multicentric, phase IIb randomized trial recruited 333 new culture-positive, drug-sensitive adult patients with pulmonary tuberculosis to compare safety and efficacy of high-dose rifampicin (R25/R35), against conventional dose (R10) given daily for 8 weeks followed by standard doses for 16 weeks...
March 2024: Open Forum Infectious Diseases